Skullcapflavone II Suppresses Colorectal Cancer by Inhibiting the HIF ‐1α‐Glycolysis Pathway
Chemical Biology & Drug Design · 2025
DOI: 10.1111/cbdd.70184 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2025. Verfasst von Shiwei Yang und 3 weiteren Autor:innen. Beteiligte Einrichtung: First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Flavonoids, Glycolysis, Hypoxia-Inducible Factor 1, alpha Subunit. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Jinan Clinical Medical Science and Technology Innovation Plan, Shandong-Chongqing Science and Technology Cooperation Project.
Abstract (Originalsprache)
Our aim is to explore Skullcapflavone II (SFII) function in colorectal cancer and delineate its relevant mechanisms. Malignant behaviors of HCT‐116 and SW480 cells were assessed using colony formation, 5‐ethynyl‐2′‐deoxyuridine staining, Annexin V/propidium iodide double staining, scratch and transwell assays. Changes in glycolysis were assessed by seahorse assay and western blot. The potential mechanism by which SFII inhibited the expression of hypoxia‐inducible transcription factor‐1alpha (HIF‐1α) was explored in vitro by molecular docking, surface plasmon resonance, quantitative reverse transcription polymerase chain reaction, western blot, immunofluorescence, cycloheximide chase assay, ubiquitination assay, and some rescue experiments. Besides, a xenograft model was performed to verify SFII function on colorectal cancer. We found that SFII inhibited the malignant behavior and glycolysis of colorectal cancer cells. Furthermore, SFII inhibited HIF‐1α protein level in colorectal cancer cells via enhancing its ubiquitination. Moreover, HIF‐1α overexpression attenuated SFII effect on the malignant behavior and glycolysis in colorectal cancer cells. In vivo, SFII inhibited tumorigenesis through repressing the HIF‐1α‐glycolysis pathway in BALB/c nude mice. SFII could suppress proliferation, migration, and invasion in colorectal cancer through inhibiting the HIF‐1α‐glycolysis pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
- Department of Health Management, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Engineering Research Center of Health Management, Jinan, Shandong,…
- Department of General Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.
ORCID-Profile: Guang Zhang
Förderung
- Jinan Clinical Medical Science and Technology Innovation Plan
- Shandong-Chongqing Science and Technology Cooperation Project
Zitieren
APA
Yang, S., Hu, W., Xin, X., & Zhang, G. (2025). Skullcapflavone II Suppresses Colorectal Cancer by Inhibiting the HIF ‐1α‐Glycolysis Pathway. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70184
Vancouver
Yang S, Hu W, Xin X, Zhang G. Skullcapflavone II Suppresses Colorectal Cancer by Inhibiting the HIF ‐1α‐Glycolysis Pathway. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70184
BibTeX
@article{Yang2025,
author = {Yang, Shiwei and Hu, Wenqi and Xin, Xuezhi and Zhang, Guang},
title = {Skullcapflavone II Suppresses Colorectal Cancer by Inhibiting the HIF ‐1α‐Glycolysis Pathway},
journal = {Chemical Biology & Drug Design},
year = {2025},
doi = {10.1111/cbdd.70184}
}
EUVIMED